Month: September 2026

MONTREAL, Sept. 28, 2026 (GLOBE NEWSWIRE) — Troilus Mining Corp. (“Troilus” or the “Company”) (TSX: TLG; OTCQX: CHXMF; FSE: CM5) is pleased to announce that it has received a credit-approved commitment letter from KfW IPEX-Bank and Societe Generale to underwrite a total of US$850 million in debt financing to support the development of its Troilus Gold-Copper Project (the “Project”) in Québec, Canada (the “Commitment Letter”). This commitment forms part of a planned total anticipated US$1.1 billion debt financing package, which includes a proposed US$250 million contribution from Export Development Canada (“EDC”) that remains subject to EDC’s final approvals.

The Commitment Letter represents a major advancement under the Company’s previously announced debt financing mandate (see May 5, 2026 press release), moving a substantial portion of the proposed debt package from mandate to credit-approved underwriting commitments. The approvals follow extensive technical, environmental, social and financial due diligence by the lenders and mark an important step toward a fully funded construction decision.

Justin Reid, CEO of Troilus, commented, “These credit approvals represent one of the most significant financing milestones in Troilus’s development to date. The underwriting commitments from KfW IPEX-Bank and Societe Generale reflect the depth of work undertaken to establish the Project’s technical and economic foundations and advance our execution plan. With US$850 million in credit-approved commitments, we have taken a substantial step toward assembling the funding required to build Troilus. Our focus is now on completing the broader financing package to reach a final investment decision and financial close, while advancing permitting, detailed engineering and procurement to support construction readiness.”

Debt Financing Structure and Terms

The commitments from KfW IPEX-Bank and Societe Generale (together, the “Commercial Lenders”) comprise senior secured project finance facilities (the “Debt Facilities”) expected to form a cornerstone of the Project’s overall financing package. The Commitment Letter is subject to various conditions precedent, including, but not limited to, receiving debt commitments for the total US$1.1 billion facility, receiving approvals from each applicable export credit agency, finalization of ongoing diligence, execution of definitive documents and support arrangements, there being no material adverse change and receipt of all required regulatory approvals, among other conditions.

Structured with anticipated support from European export credit agencies, the Debt Facilities feature competitive interest margins consistent with export credit-backed project financings involving leading international lenders and sovereign support. The proposed structure combines attractive pricing with an extended repayment profile, providing a cost-effective source of capital aligned with the Project’s development and operating requirements.

The Debt Facilities include up to a three-year repayment grace period during construction, followed by a sculpted repayment profile over a notional 10-year period aligned with expected cash flow generation. Final terms and further details are expected to be disclosed upon execution of definitive financing documentation.

EDC, one of the Project’s three mandated lead arrangers alongside the Commercial Lenders, continues to advance its approval process for a proposed US$250 million financing contribution. If approved, this contribution would bring total credit-approved debt commitments to US$1.1 billion. Troilus is also working with the participating European export credit agencies on the remaining approvals and support arrangements for the broader debt financing package.

The Project represents a significant opportunity to expand Canada’s copper and gold exports, strengthen long-term supply relationships with trusted European trading partners, and deliver lasting economic benefits for Québec and Canada. As a mandated lead arranger, EDC is working closely with the lending syndicate and participating European export credit agencies to advance the financing while continuing to work toward its final approvals.

Advancing Toward Financial Close

Building on these commitments, Troilus and its project finance advisor, Auramet International Inc. (“Auramet”), are focused on finalizing definitive facility agreements, completing the broader financing package and satisfying the various conditions and completion requirements to reach a final investment decision and financial close.

Qualified Persons

The technical and scientific information in this press release has been reviewed and approved by Denis Rivard, P.Eng., EVP Projects, who is a Qualified Person as defined by NI 43-101. Mr. Rivard is an employee of Troilus and is not independent of the Company under NI 43-101.

About Troilus Mining Corp.

Troilus Mining Corp. is a Canadian development-stage mining company focused on the systematic advancement of the former gold and copper Troilus Mine towards production. Troilus is located in the tier-one mining jurisdiction of Quebec, Canada, where it holds a large land position of 435 km² in the Frôtet-Evans Greenstone Belt. The Technical Report outlines a large-scale, approximately 26-year, 50ktpd open-pit mining operation, positioning it as a cornerstone project in North America.

For more information:

Caroline Arsenault
VP Corporate Communications
+1 (647) 276-0050
info@troilusmining.com  

Cautionary Note Regarding Forward-Looking Statements and Information

This press release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking statements”). Forward-looking statements include, but are not limited to, statements regarding the anticipated completion, amount, structure and terms of the Debt Facilities and the broader project financing package; the expected role of the Debt Facilities in funding the development and construction of the Troilus Project; anticipated pricing, repayment grace periods and repayment schedules; the receipt of remaining approvals from Export Development Canada and participating European export credit agencies and the finalization of related support arrangements; the negotiation and execution of definitive financing documentation and key project contracts; the satisfaction of conditions precedent and other funding and completion requirements; the availability and drawdown of funds; the timing and achievement of a final investment decision and financial close; the anticipated disclosure of final financing terms; the advancement of permitting, detailed engineering and procurement; the timing and commencement of construction and the future development and operation of the Troilus Project; and the Project’s potential to expand Canadian copper and gold exports, strengthen supply relationships with European trading partners and generate long-term economic benefits for Québec and Canada.

Generally, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “continue”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “will”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking statements are made based upon certain assumptions and other important facts that, if untrue, could cause the actual results, performances or achievements of Troilus to be materially different from future results, performances or achievements expressed or implied by such statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Troilus will operate in the future. Certain important factors that could cause actual results, performances or achievements to differ materially from those in the forward-looking statements include, amongst others, currency fluctuations, the global economic climate, dilution, share price volatility and competition. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results, level of activity, performance or achievements of Troilus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: the risk that the Debt Facilities may not be completed on the anticipated terms, including the risk that definitive documentation may not be finalized and executed on a timely basis and that the customary project finance terms and conditions, including conditions precedent to drawdown, may not be satisfied; uncertainties with respect to receiving approval for the additional contribution for the planned financing package; risks and uncertainties inherent to mineral resource and reserve estimates; the high degree of uncertainties inherent to feasibility studies and other mining and economic studies which are based to a significant extent on various assumptions; variations in gold prices and other metals, exchange rate fluctuations; variations in cost of supplies and labour; receipt of necessary approvals; availability of financing for project development; uncertainties and risks with respect to developing mining projects; general business, economic, competitive, political and social uncertainties; future gold and other metal prices; accidents, labour disputes and shortages; environmental and other risks of the mining industry, including without limitation, risks and uncertainties discussed in the Company’s latest Annual Information Form, its technical reports and other continuous disclosure documents of the Company available under the Company’s profile at www.sedarplus.ca. Although Troilus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Troilus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.

New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray Brands

ELLON, Scotland and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE) — BrewDog, a leader in U.K. craft beer and one of the world’s most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), today announced a series of senior leadership appointments designed to strengthen execution, sharpen brand and commercial focus, and support BrewDog’s next phase of growth across the United Kingdom and international markets.

The appointments reflect BrewDog’s continued investment in the people, capabilities, and leadership needed to unlock the full potential of its iconic global brand and build on the momentum of its next chapter as part of the Tilray Brands family.

The senior leadership appointments include:

• John Beasley, Chief Marketing Officer — leads BrewDog’s marketing strategy, with responsibility for strengthening brand building, consumer engagement and commercial momentum across key markets. With more than 25 years of beverage marketing experience, including leadership roles at Red Bull and Monster Energy, John brings proven brand-building expertise and a global perspective to support BrewDog’s next phase of growth.
• Gemma Hampton-Stone, Managing Director of Bars and Hospitality — leads BrewDog’s bars and hospitality business, with responsibility for creating standout customer experiences while strengthening performance and growth across the hospitality estate. With nearly two decades of hospitality leadership experience, including overseeing a portfolio of more than 36 pubs, restaurants, hotels and live music venues, Gemma brings the operational expertise and customer-first mindset needed to strengthen BrewDog’s bars business and enhance the guest experience.
• Ridesh Sharma, Category Director — leads BrewDog’s category strategy, with responsibility for sharpening the portfolio, deepening customer and consumer insight, and identifying growth opportunities across markets. Ridesh combines category, commercial, and revenue growth expertise with a strong understanding of customer needs, making him ideally suited to strengthen BrewDog’s portfolio and support its next phase of growth.
• Faisal Khan, Commercial Director, Beverages – Rest of the World (ROW) — leads BrewDog’s commercial efforts across international markets outside Europe, with responsibility for identifying new opportunities and accelerating growth across BrewDog’s global portfolio. Faisal’s extensive experience building businesses and managing distributor networks across high-growth international markets makes him ideally positioned to accelerate BrewDog’s expansion and unlock new opportunities around the world.

Rajnish Ohri, President, International at Tilray Brands, said, “We are entering an exciting new chapter for BrewDog — one defined by renewed ambition, stronger execution and a clear vision for the future. BrewDog is an iconic global brand with an incredible community, talented people, great beer and enormous potential. As part of the Tilray Brands family, we are investing in the leadership, capabilities and focus needed to build on everything that has made BrewDog special while bringing even greater ambition to where we go next.”

Mr. Ohri continued, “These appointments reflect our commitment to building a stronger BrewDog for the future, with the right people empowered to lead and the focus, energy and leadership needed to execute effectively. Our ambition is clear: to make BrewDog stronger, continue to innovate and lead, and build one of the world’s most exciting and influential craft beer brands for the long term. BrewDog’s next chapter is underway, and we believe its best years are ahead.”

Together, the strengthened leadership bench brings additional focus across brand building, consumer engagement, hospitality, category strategy and international commercial growth, supporting BrewDog’s strategy to strengthen the core brand, accelerate innovation and unlock opportunities across retail, hospitality and global markets.

With an expanded leadership team, the strength and scale of Tilray Brands behind it, and a clear focus on long-term growth, BrewDog is building for the future with renewed momentum, stronger execution and confidence in what its teams can accomplish together.

About BrewDog  
BrewDog has always had one mission: to make people as passionate about great beer as we are.  From iconic classics like Punk IPA, to crowd-pleasers like Lost Lager and Wingman, to boundary-pushing innovations like NanoDog, BrewDog has been brewing bold, distinctive beers since 2007. Born in Scotland and built by a passionate community of beer lovers, BrewDog has grown into one of the world’s most recognisable craft beer brands, with a global presence spanning breweries, bars and distribution across multiple international markets. BrewDog’s future continues to be shaped by the three things that matter most: People, Planet and Beer.

For more information, visit www.brewdog.com or follow @BrewDog on social media.  

About Tilray Brands 
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages. 

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. 

Forward-Looking Statements
 Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.  

Tilray Brands Contacts:
Media 
news@tilray.com

Investor Relations 
investors@tilray.com

New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray Brands

ELLON, Scotland and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE) — BrewDog, a leader in U.K. craft beer and one of the world’s most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), today announced a series of senior leadership appointments designed to strengthen execution, sharpen brand and commercial focus, and support BrewDog’s next phase of growth across the United Kingdom and international markets.

The appointments reflect BrewDog’s continued investment in the people, capabilities, and leadership needed to unlock the full potential of its iconic global brand and build on the momentum of its next chapter as part of the Tilray Brands family.

The senior leadership appointments include:

• John Beasley, Chief Marketing Officer — leads BrewDog’s marketing strategy, with responsibility for strengthening brand building, consumer engagement and commercial momentum across key markets. With more than 25 years of beverage marketing experience, including leadership roles at Red Bull and Monster Energy, John brings proven brand-building expertise and a global perspective to support BrewDog’s next phase of growth.
• Gemma Hampton-Stone, Managing Director of Bars and Hospitality — leads BrewDog’s bars and hospitality business, with responsibility for creating standout customer experiences while strengthening performance and growth across the hospitality estate. With nearly two decades of hospitality leadership experience, including overseeing a portfolio of more than 36 pubs, restaurants, hotels and live music venues, Gemma brings the operational expertise and customer-first mindset needed to strengthen BrewDog’s bars business and enhance the guest experience.
• Ridesh Sharma, Category Director — leads BrewDog’s category strategy, with responsibility for sharpening the portfolio, deepening customer and consumer insight, and identifying growth opportunities across markets. Ridesh combines category, commercial, and revenue growth expertise with a strong understanding of customer needs, making him ideally suited to strengthen BrewDog’s portfolio and support its next phase of growth.
• Faisal Khan, Commercial Director, Beverages – Rest of the World (ROW) — leads BrewDog’s commercial efforts across international markets outside Europe, with responsibility for identifying new opportunities and accelerating growth across BrewDog’s global portfolio. Faisal’s extensive experience building businesses and managing distributor networks across high-growth international markets makes him ideally positioned to accelerate BrewDog’s expansion and unlock new opportunities around the world.

Rajnish Ohri, President, International at Tilray Brands, said, “We are entering an exciting new chapter for BrewDog — one defined by renewed ambition, stronger execution and a clear vision for the future. BrewDog is an iconic global brand with an incredible community, talented people, great beer and enormous potential. As part of the Tilray Brands family, we are investing in the leadership, capabilities and focus needed to build on everything that has made BrewDog special while bringing even greater ambition to where we go next.”

Mr. Ohri continued, “These appointments reflect our commitment to building a stronger BrewDog for the future, with the right people empowered to lead and the focus, energy and leadership needed to execute effectively. Our ambition is clear: to make BrewDog stronger, continue to innovate and lead, and build one of the world’s most exciting and influential craft beer brands for the long term. BrewDog’s next chapter is underway, and we believe its best years are ahead.”

Together, the strengthened leadership bench brings additional focus across brand building, consumer engagement, hospitality, category strategy and international commercial growth, supporting BrewDog’s strategy to strengthen the core brand, accelerate innovation and unlock opportunities across retail, hospitality and global markets.

With an expanded leadership team, the strength and scale of Tilray Brands behind it, and a clear focus on long-term growth, BrewDog is building for the future with renewed momentum, stronger execution and confidence in what its teams can accomplish together.

About BrewDog  
BrewDog has always had one mission: to make people as passionate about great beer as we are.  From iconic classics like Punk IPA, to crowd-pleasers like Lost Lager and Wingman, to boundary-pushing innovations like NanoDog, BrewDog has been brewing bold, distinctive beers since 2007. Born in Scotland and built by a passionate community of beer lovers, BrewDog has grown into one of the world’s most recognisable craft beer brands, with a global presence spanning breweries, bars and distribution across multiple international markets. BrewDog’s future continues to be shaped by the three things that matter most: People, Planet and Beer.

For more information, visit www.brewdog.com or follow @BrewDog on social media.  

About Tilray Brands 
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages. 

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. 

Forward-Looking Statements
 Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.  

Tilray Brands Contacts:
Media 
news@tilray.com

Investor Relations 
investors@tilray.com

Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027

Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, 2026, in San Diego, CA. BH-501284 is a novel, orally bioavailable, non-covalent, pseudo-irreversible pan-KRAS inhibitor designed to overcome limitations of current KRAS-targeted therapies.

“KRAS mutation has historically been one of the most challenging oncogenic drivers to target, and while recent advances have validated its therapeutic potential, we believe there remains an opportunity to develop a pan-KRAS inhibitor capable of delivering potent and durable target inhibition across a broad range of KRAS mutations,” said Jean Cui, Ph.D., Founder and Chief Executive Officer of BlossomHill Therapeutics. “We designed BH-501284 with a novel Switch-II chemical scaffold and pseudo-irreversible binding characteristics intended to achieve prolonged, potent and selective inhibition of KRAS mutations, which we believe may result in improved efficacy and tolerability. These preclinical data demonstrate sustained KRAS pathway suppression, and deep and durable antitumor activity across multiple KRAS-mutant tumor models, further supporting the advancement of BH-501284 toward an IND submission in Q12027.”

Presentation highlights:

• BH-501284 exhibited potent and prolonged activity across a broad range of KRAS mutations. BH-501284 showed a target residence time of more than 54 hours in a SPR study using GDP- state KRAS G12D protein, extended KRAS signaling inhibition in KRAS-mutant cell lines, and potent cellular activity across multiple KRAS mutations, while sparing HRAS and NRAS.
• BH-501284 showed deep and durable antitumor activity across multiple preclinical KRAS-mutant tumor models. Treatment resulted in tumor regression across pancreatic, lung and colorectal cancer models with KRAS G12V, D or C mutation at relatively low doses. In a KRAS G12C lung cancer model, pseudo-irreversible BH-501284 achieved tumor regression comparable to covalent, irreversible KRAS G12C inhibitors.
• BH-501284 demonstrated deeper and more durable tumor regression than tricomplex RAS inhibitors. In a KRAS G12D pancreatic cancer model, BH-501284 achieved deeper and more durable tumor regression than tricomplex inhibitors when administered at similar doses.
• BH-501284 also demonstrated the potential to combine with an anti-PD-1 treatment. In a KRAS G12D colorectal cancer model, the combination demonstrated prolonged survival compared with either treatment alone.

About BH-501284
BH-501284 is an investigational, orally bioavailable pan-KRAS inhibitor, which utilizes a novel Switch-II chemical scaffold to achieve prolonged, potent and selective inhibition of KRAS mutations. We believe this molecule, which uses a non-covalent scaffold, is unique in its potential to achieve tight and durable binding, a feature described as “pseudo-irreversible” binding. In preclinical studies, BH-501284 demonstrated sustained blocking of KRAS signaling leading to deeper and more durable antitumor activities in KRAS mutant cells and tumor models at low dose levels.

About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical program is BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR™ inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company’s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch-II inhibitor for potential future development in diverse KRAS-mutant tumors.

BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit bhtherapeutics.com and follow us on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws, including, without limitation, statements regarding: the therapeutic potential, clinical benefits, safety and potential competitive differentiation of the company’s product candidates, including BH-30643, BH-30236 and BH-501284; the design, enrollment, timing, progress and results of the company’s clinical trials and preclinical studies; the company’s planned regulatory interactions and submissions; anticipated program milestones, including the timing of program and data updates; statements by the company’s management; and the company’s development plans and continued advancement of its pipeline. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “upcoming,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially, including, without limitation: the company’s limited operating history, history of significant losses and the early stage of development of its product candidates; the risk that preclinical data may not be predictive of results in clinical trials; the risk that preliminary and interim clinical data are subject to further analysis and may not be predictive of, may be inconsistent with, or may be more favorable than, data generated as clinical trials continue or data from future clinical trials; uncertainties inherent in the initiation, timing, design and enrollment of clinical trials, and the availability and timing of data from ongoing and future trials; the company’s ability to successfully demonstrate the safety and efficacy of its product candidates and to obtain and maintain regulatory approvals; the timing and outcome of planned interactions with, and submissions to, the FDA and other regulatory authorities, including whether an accelerated approval pathway will be available to the company; competition from third parties that are developing products for similar indications; the prior success of the company’s management team not being indicative of future success; the company’s reliance on third parties, including contract research organizations and contract manufacturing organizations; the company’s ability to obtain, maintain and protect its intellectual property; and the company’s need for additional financing and its estimates regarding operating expenses and capital requirements. These and other risks are described in greater detail under the heading “Risk Factors” in the company’s filings with the Securities and Exchange Commission (the “SEC”), including the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as well as in the company’s subsequent filings with the SEC. Any forward-looking statements represent the company’s views only as of the date of this press release, and the company expressly disclaims any obligation to update any forward-looking statements, except as required by law.

Company Contact:
Michael Moore, BlossomHill Therapeutics
michael.moore@bhtherapeutics.com

Media:
Ashlea Kosikowski, 1AB
ashlea@1abmedia.com

Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027

Novel Switch-II scaffold and pseudo-irreversible binding designed to enable prolonged, potent and selective inhibition of mutant KRAS to potentially achieve improved efficacy and tolerability

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, 2026, in San Diego, CA. BH-501284 is a novel, orally bioavailable, non-covalent, pseudo-irreversible pan-KRAS inhibitor designed to overcome limitations of current KRAS-targeted therapies.

“KRAS mutation has historically been one of the most challenging oncogenic drivers to target, and while recent advances have validated its therapeutic potential, we believe there remains an opportunity to develop a pan-KRAS inhibitor capable of delivering potent and durable target inhibition across a broad range of KRAS mutations,” said Jean Cui, Ph.D., Founder and Chief Executive Officer of BlossomHill Therapeutics. “We designed BH-501284 with a novel Switch-II chemical scaffold and pseudo-irreversible binding characteristics intended to achieve prolonged, potent and selective inhibition of KRAS mutations, which we believe may result in improved efficacy and tolerability. These preclinical data demonstrate sustained KRAS pathway suppression, and deep and durable antitumor activity across multiple KRAS-mutant tumor models, further supporting the advancement of BH-501284 toward an IND submission in Q12027.”

Presentation highlights:

• BH-501284 exhibited potent and prolonged activity across a broad range of KRAS mutations. BH-501284 showed a target residence time of more than 54 hours in a SPR study using GDP- state KRAS G12D protein, extended KRAS signaling inhibition in KRAS-mutant cell lines, and potent cellular activity across multiple KRAS mutations, while sparing HRAS and NRAS.
• BH-501284 showed deep and durable antitumor activity across multiple preclinical KRAS-mutant tumor models. Treatment resulted in tumor regression across pancreatic, lung and colorectal cancer models with KRAS G12V, D or C mutation at relatively low doses. In a KRAS G12C lung cancer model, pseudo-irreversible BH-501284 achieved tumor regression comparable to covalent, irreversible KRAS G12C inhibitors.
• BH-501284 demonstrated deeper and more durable tumor regression than tricomplex RAS inhibitors. In a KRAS G12D pancreatic cancer model, BH-501284 achieved deeper and more durable tumor regression than tricomplex inhibitors when administered at similar doses.
• BH-501284 also demonstrated the potential to combine with an anti-PD-1 treatment. In a KRAS G12D colorectal cancer model, the combination demonstrated prolonged survival compared with either treatment alone.

About BH-501284
BH-501284 is an investigational, orally bioavailable pan-KRAS inhibitor, which utilizes a novel Switch-II chemical scaffold to achieve prolonged, potent and selective inhibition of KRAS mutations. We believe this molecule, which uses a non-covalent scaffold, is unique in its potential to achieve tight and durable binding, a feature described as “pseudo-irreversible” binding. In preclinical studies, BH-501284 demonstrated sustained blocking of KRAS signaling leading to deeper and more durable antitumor activities in KRAS mutant cells and tumor models at low dose levels.

About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical program is BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR™ inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company’s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch-II inhibitor for potential future development in diverse KRAS-mutant tumors.

BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit bhtherapeutics.com and follow us on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws, including, without limitation, statements regarding: the therapeutic potential, clinical benefits, safety and potential competitive differentiation of the company’s product candidates, including BH-30643, BH-30236 and BH-501284; the design, enrollment, timing, progress and results of the company’s clinical trials and preclinical studies; the company’s planned regulatory interactions and submissions; anticipated program milestones, including the timing of program and data updates; statements by the company’s management; and the company’s development plans and continued advancement of its pipeline. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “upcoming,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially, including, without limitation: the company’s limited operating history, history of significant losses and the early stage of development of its product candidates; the risk that preclinical data may not be predictive of results in clinical trials; the risk that preliminary and interim clinical data are subject to further analysis and may not be predictive of, may be inconsistent with, or may be more favorable than, data generated as clinical trials continue or data from future clinical trials; uncertainties inherent in the initiation, timing, design and enrollment of clinical trials, and the availability and timing of data from ongoing and future trials; the company’s ability to successfully demonstrate the safety and efficacy of its product candidates and to obtain and maintain regulatory approvals; the timing and outcome of planned interactions with, and submissions to, the FDA and other regulatory authorities, including whether an accelerated approval pathway will be available to the company; competition from third parties that are developing products for similar indications; the prior success of the company’s management team not being indicative of future success; the company’s reliance on third parties, including contract research organizations and contract manufacturing organizations; the company’s ability to obtain, maintain and protect its intellectual property; and the company’s need for additional financing and its estimates regarding operating expenses and capital requirements. These and other risks are described in greater detail under the heading “Risk Factors” in the company’s filings with the Securities and Exchange Commission (the “SEC”), including the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as well as in the company’s subsequent filings with the SEC. Any forward-looking statements represent the company’s views only as of the date of this press release, and the company expressly disclaims any obligation to update any forward-looking statements, except as required by law.

Company Contact:
Michael Moore, BlossomHill Therapeutics
michael.moore@bhtherapeutics.com

Media:
Ashlea Kosikowski, 1AB
ashlea@1abmedia.com

Amended and Extended Credit Agreement for Revolver and Term Loan A Facility and Issued a New $500 Million Term Loan B

LOUISVILLE, Ky., Sept. 28, 2026 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (Nasdaq: CHDN, “CDI,” “the Company”) announced today that CDI successfully closed its amended and extended Credit Facility and new Term Loan B (“2033 TLB”).

CDI closed an amendment to its senior secured credit agreement (the “Credit Agreement Amendment”) to extend the maturity date of its existing revolving credit facility and term loan A facility from 2029 to 2031 and to make certain other changes to its existing credit agreement.   The interest rate applicable to borrowings on the Credit Agreement Amendment will be SOFR-based plus a spread, determined by CDI’s total net leverage ratio.

CDI also closed its previously announced $500 million in aggregate principal amount of senior secured Term Loan B due 2033 (“2033 TLB”). The 2033 TLB has an interest rate of SOFR plus 175 basis points and issued at 99.875% of the principal amount.

CDI intends to use the net proceeds from 2033 TLB (i) to repay outstanding Term Loan B loans, (ii) to repay outstanding revolving loans, (iii) to fund related transaction fees and expenses, and (iv) for working capital and other general corporate purposes.

On September 18, 2026, CDI issued a conditional redemption notice to redeem the 5.50% Senior Notes due 2027 (the “2027 Notes”) on October 19, 2026. CDI intends to fund the 2027 Notes redemption amount from its revolving credit facility.

About Churchill Downs Incorporated

Churchill Downs Incorporated (“CDI”) (Nasdaq: CHDN) has created extraordinary entertainment experiences for over 150 years, beginning with the Company’s most iconic and enduring asset, Churchill Downs Racetrack, the home of the Kentucky Derby and premier races of the Thoroughbred Championship Series. Headquartered in Louisville, Kentucky, CDI has expanded through the acquisition, development, and operation of live and historical racing entertainment venues, the growth of the online wagering businesses, and the acquisition, development, and operation of regional casino gaming properties. https://www.churchilldownsincorporated.com/

This news release contains various “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by the use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “seek,” “should,” “will,” “scheduled,” and similar words or similar expressions (or negative versions of such words or expressions), although some forward-looking statements are expressed differently.

Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could cause actual results to differ materially from expectations include the following: the occurrence of extraordinary events, such as terrorist attacks, public health threats, civil unrest, and inclement weather, including as a result of climate change; the effect of economic conditions on our consumers’ confidence and discretionary spending or our access to credit, including the impact of inflation; changes in, or new interpretations of, applicable tax laws or rulings that could result in additional tax liabilities; the impact of any pandemics, epidemics, or outbreaks of infectious diseases, and related economic matters on our results of operations, financial conditions, and prospects; lack of confidence in the integrity of our core businesses or any deterioration in our reputation; negative shifts in public opinion regarding gambling that could result in increased regulation of, or new restrictions on, the gaming industry; loss of key or highly skilled personnel, as well as general disruptions in the general labor market; the impact of significant competition, and the expectation that competition levels will increase; changes in consumer preferences, attendance, wagering, and sponsorships; risks associated with equity investments, strategic alliances and other third-party agreements; inability to respond to rapid technological changes in a timely manner; concentration and evolution of slot machine and historical racing machine manufacturing and other technology conditions that could impose additional costs; failure to enter into or maintain agreements with industry constituents, including horsemen and other racetracks; cybersecurity risk, including cybersecurity breaches, loss or misuse of our confidential information as a result of a breach including customers’ personal information, or IT system operational disruptions, could lead to government enforcement actions or other litigation; costs of compliance with increasingly complex laws and regulations regarding data privacy and protection of personal information; reliance on our technology services and catastrophic events, system failures, errors or defects disrupting our operations; inability to identify, complete, or fully realize the benefits of our proposed acquisitions, divestitures, development of new venues or the expansion of existing facilities on time, on budget, or as planned; difficulty in integrating recent or future acquisitions into our operations; cost overruns and other uncertainties associated with the development of new venues and the expansion of existing facilities; general risks related to real estate ownership and significant expenditures, including risks related to environmental liabilities; personal injury litigation related to injuries occurring at our racetracks; compliance with the Foreign Corrupt Practices Act or other similar laws and regulations, or applicable anti-money laundering regulations; payment-related risks, such as risk associated with fraudulent credit card or debit card use; work stoppages and labor problems; risks related to pending or future legal proceedings and other actions; highly regulated operations and changes in the regulatory environment could adversely affect our business; restrictions in our debt facilities limiting our flexibility to operate our business; failure to comply with the financial ratios and other covenants in our debt facilities and other indebtedness; increases to interest rates, disruption in the credit markets or changes to our credit ratings may adversely affect our business; increase in our insurance costs, or inability to obtain similar insurance coverage in the future, and any inability to recover under our insurance policies for damages sustained at our properties in the event of inclement weather and casualty events; whether the objective of a strategic alternative review process will be achieved; the terms, structure, benefits and costs of any strategic transaction; the timing of any strategic transaction and whether any strategic transaction will be consummated on the terms proposed or at all; the risk that the announcement or exploration of strategic alternatives could have an adverse effect on our ability to retain key personnel and maintain relationships with partners, suppliers, employees, shareholders and other business relationships; the risk of any unexpected costs or expenses resulting from the exploration of strategic alternatives; the risk of any litigation relating to the exploration of strategic alternatives or any strategic transaction; and other factors described under the heading “Risk Factors” in our most recent Annual Report on Form 10-K and in other filings we make with the Securities and Exchange Commission.

We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact: Sam Ullrich                                        
(502) 638-3906                                                        
Sam.Ullrich@kyderby.com     

This press release was published by a CLEAR® Verified individual.

Amended and Extended Credit Agreement for Revolver and Term Loan A Facility and Issued a New $500 Million Term Loan B

LOUISVILLE, Ky., Sept. 28, 2026 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (Nasdaq: CHDN, “CDI,” “the Company”) announced today that CDI successfully closed its amended and extended Credit Facility and new Term Loan B (“2033 TLB”).

CDI closed an amendment to its senior secured credit agreement (the “Credit Agreement Amendment”) to extend the maturity date of its existing revolving credit facility and term loan A facility from 2029 to 2031 and to make certain other changes to its existing credit agreement.   The interest rate applicable to borrowings on the Credit Agreement Amendment will be SOFR-based plus a spread, determined by CDI’s total net leverage ratio.

CDI also closed its previously announced $500 million in aggregate principal amount of senior secured Term Loan B due 2033 (“2033 TLB”). The 2033 TLB has an interest rate of SOFR plus 175 basis points and issued at 99.875% of the principal amount.

CDI intends to use the net proceeds from 2033 TLB (i) to repay outstanding Term Loan B loans, (ii) to repay outstanding revolving loans, (iii) to fund related transaction fees and expenses, and (iv) for working capital and other general corporate purposes.

On September 18, 2026, CDI issued a conditional redemption notice to redeem the 5.50% Senior Notes due 2027 (the “2027 Notes”) on October 19, 2026. CDI intends to fund the 2027 Notes redemption amount from its revolving credit facility.

About Churchill Downs Incorporated

Churchill Downs Incorporated (“CDI”) (Nasdaq: CHDN) has created extraordinary entertainment experiences for over 150 years, beginning with the Company’s most iconic and enduring asset, Churchill Downs Racetrack, the home of the Kentucky Derby and premier races of the Thoroughbred Championship Series. Headquartered in Louisville, Kentucky, CDI has expanded through the acquisition, development, and operation of live and historical racing entertainment venues, the growth of the online wagering businesses, and the acquisition, development, and operation of regional casino gaming properties. https://www.churchilldownsincorporated.com/

This news release contains various “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by the use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “seek,” “should,” “will,” “scheduled,” and similar words or similar expressions (or negative versions of such words or expressions), although some forward-looking statements are expressed differently.

Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could cause actual results to differ materially from expectations include the following: the occurrence of extraordinary events, such as terrorist attacks, public health threats, civil unrest, and inclement weather, including as a result of climate change; the effect of economic conditions on our consumers’ confidence and discretionary spending or our access to credit, including the impact of inflation; changes in, or new interpretations of, applicable tax laws or rulings that could result in additional tax liabilities; the impact of any pandemics, epidemics, or outbreaks of infectious diseases, and related economic matters on our results of operations, financial conditions, and prospects; lack of confidence in the integrity of our core businesses or any deterioration in our reputation; negative shifts in public opinion regarding gambling that could result in increased regulation of, or new restrictions on, the gaming industry; loss of key or highly skilled personnel, as well as general disruptions in the general labor market; the impact of significant competition, and the expectation that competition levels will increase; changes in consumer preferences, attendance, wagering, and sponsorships; risks associated with equity investments, strategic alliances and other third-party agreements; inability to respond to rapid technological changes in a timely manner; concentration and evolution of slot machine and historical racing machine manufacturing and other technology conditions that could impose additional costs; failure to enter into or maintain agreements with industry constituents, including horsemen and other racetracks; cybersecurity risk, including cybersecurity breaches, loss or misuse of our confidential information as a result of a breach including customers’ personal information, or IT system operational disruptions, could lead to government enforcement actions or other litigation; costs of compliance with increasingly complex laws and regulations regarding data privacy and protection of personal information; reliance on our technology services and catastrophic events, system failures, errors or defects disrupting our operations; inability to identify, complete, or fully realize the benefits of our proposed acquisitions, divestitures, development of new venues or the expansion of existing facilities on time, on budget, or as planned; difficulty in integrating recent or future acquisitions into our operations; cost overruns and other uncertainties associated with the development of new venues and the expansion of existing facilities; general risks related to real estate ownership and significant expenditures, including risks related to environmental liabilities; personal injury litigation related to injuries occurring at our racetracks; compliance with the Foreign Corrupt Practices Act or other similar laws and regulations, or applicable anti-money laundering regulations; payment-related risks, such as risk associated with fraudulent credit card or debit card use; work stoppages and labor problems; risks related to pending or future legal proceedings and other actions; highly regulated operations and changes in the regulatory environment could adversely affect our business; restrictions in our debt facilities limiting our flexibility to operate our business; failure to comply with the financial ratios and other covenants in our debt facilities and other indebtedness; increases to interest rates, disruption in the credit markets or changes to our credit ratings may adversely affect our business; increase in our insurance costs, or inability to obtain similar insurance coverage in the future, and any inability to recover under our insurance policies for damages sustained at our properties in the event of inclement weather and casualty events; whether the objective of a strategic alternative review process will be achieved; the terms, structure, benefits and costs of any strategic transaction; the timing of any strategic transaction and whether any strategic transaction will be consummated on the terms proposed or at all; the risk that the announcement or exploration of strategic alternatives could have an adverse effect on our ability to retain key personnel and maintain relationships with partners, suppliers, employees, shareholders and other business relationships; the risk of any unexpected costs or expenses resulting from the exploration of strategic alternatives; the risk of any litigation relating to the exploration of strategic alternatives or any strategic transaction; and other factors described under the heading “Risk Factors” in our most recent Annual Report on Form 10-K and in other filings we make with the Securities and Exchange Commission.

We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact: Sam Ullrich                                        
(502) 638-3906                                                        
Sam.Ullrich@kyderby.com     

This press release was published by a CLEAR® Verified individual.

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — GoldInxs Mining Corp. (the “Company” or “GoldInxs”) is pleased to announce a private placement of units (the “Units”) and Critical Mineral Exploration Tax Credit (“CMETC”) flow-through units (the “FT Units”) of the Company at a price of $0.11 per Unit and $0.13 per FT Unit for aggregate gross proceeds of up to approximately $1,150,000 (the “Offering”). Each Unit will consist of one common share of the Company and one common share purchase warrant (a “Warrant”). Each FT Unit will consist of one common share of the Company which will qualify as a “flow-through share” within the meaning of the Income Tax Act (Canada), and one Warrant.

Each whole Warrant will entitle the holder thereof to purchase one common share of the Company at a price of $0.25 at any time on or before the date which is 24 months after the closing date of the Offering, subject to the Acceleration Provision (as defined herein).  If the closing price of the Company’s common shares on the TSX Venture Exchange (the “TSXV”) (or such other principal exchange on which the common shares may be traded at such time) is equal to or greater than $0.50 for a period of ten consecutive trading days, the Company may, at its sole option, accelerate the expiry date of the Warrants to the date which is thirty days following the date upon which notice of the accelerated expiry date is provided by the Company (given by way of news release) (the foregoing the “Acceleration Provision”).

The Company plans to use the net proceeds of the Offering towards the exploration work and other operations at the Company’s flagship Fishpot Project in Central British Columbia among other flow-through eligible expenses, such as exploration, drilling, and sampling programs, and for general working capital purposes.

The Offering is scheduled to close on or about September 30, 2026 and is subject to receipt of all applicable regulatory approvals, including the approval of the TSXV. The securities issued in connection with the Offering are subject to a four-month hold period, in accordance with applicable securities laws and TSXV policies. 

In connection with the Offering, the Company may pay finders’ fees of up to 7% of the gross proceeds raised by the Company for the sale of Units and FT Units to subscribers directly introduced to the Company by eligible finders. In addition, the Company may issue to eligible finders non-transferable finder warrants of up to 7.0% of the aggregate number of the Units and FT Units sold to subscribers directly introduced to the Company by such eligible finders. Each finders’ warrant will entitle the holder to acquire one common share of the Company at a price of $0.11 per common share in respect of Units, or $0.13 per common share in respect of FT Units, for a term of 24 months from the date of closing of the Offering.

The purchase of securities under the Offering by related parties are expected to constitute “related party transactions” of the Company under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). It is expected pursuant to sections 5.5(b) and 5.7(1)(a) of MI 61-101, the Company will be exempt from obtaining formal valuation and minority approval of the Company’s shareholders respecting the purchase of securities under the Offering by related parties as the fair market value of securities to be purchased under the Offering is expected to be below 25% of the Company’s market capitalization as determined in accordance with MI 61-101.

Marketing Engagement

The Company announces that it has engaged Outside The Box Capital Inc. (“OTB”) of Oakville, Ontario as part of its awareness efforts to provide digital communications services under a marketing services agreement dated September 21, 2026 (the “OTB Agreement”), with services and promotional activity to commence on or after September 28, 2026. Under the OTB Agreement, OTB will distribute Company content, including video, and conduct investor communications on social media. The Agreement has a term of three (3) months, from September 28, 2026, to December 28, 2026.  For its services, the Company has agreed to pay OTB a total cash fee of $50,000, plus applicable taxes. The Company and OTB act at arm’s length, and no securities-based compensation, including options, forms part of this engagement. OTB can be contacted at 2202 Green Orchard Place, Oakville, Ontario L6H 4V4, by email at jason@outsidethebox.capital, or by telephone at (289) 259-4455. The OTB Service Agreement is subject to acceptance by the TSX Venture Exchange.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. The securities offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements.  

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Authorised for release by the Board of GoldInxs Mining Corp.

About GoldInxs

GoldInxs Mining Corp. (TSXV:INXS, OTCQB: INXGF) is a Canadian mineral exploration company focused on discovering and advancing a high-quality gold and copper project in Central British Columbia. The Company’s flagship asset is the Fishpot Property, a large epithermal gold system in central British Columbia with Blackwater-style exploration potential, and in the same region as Artemis Gold’s Blackwater Mine and Evolution Mining’s optioned Clisbako property. The Company is listed on the TSX Venture Exchange under the symbol INXS and on the OTCQB Venture Market under the symbol INXGF, and is led by an experienced management and technical team committed to disciplined exploration and value creation for shareholders.

Website: www.goldinxs.com     |     LinkedIn: LINK     |     Twitter/X: LINK

Further Information:

Barry Miller  
Executive Chairman and Director
GoldInxs Mining Corp.
T: 778.232.1878
E: barry@goldinxs.com

Forward Looking Statements:

This news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, “expects”, “is expected”, “anticipates”, “intends”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include, but are not limited to, statements relating to: the completion and closing of the Offering on the expected terms; the anticipated closing date of the Offering; the approval of the TSXV and receipt of all applicable regulatory approvals; the use of net proceeds from the Offering; the qualification of the FT Unit securities as “flow-through shares” within the meaning of the Income Tax Act (Canada) and the Company’s ability to incur and renounce qualifying Canadian exploration expenses and flow-through critical mineral mining expenditures to subscribers; the Company’s planned exploration work, drilling and sampling programs at the Fishpot Project and the Millar Project; the payment of finders’ fees and the issuance of finder warrants in connection with the Offering; the expected participation in the Offering by related parties and the availability of exemptions from the formal valuation and minority approval requirements of Multilateral Instrument 61-101.

Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including, but not limited to: the Company’s ability to complete the Offering on the terms described herein; the receipt of all necessary regulatory approvals, including the conditional approval of the TSXV; general market and economic conditions; the Company’s ability to incur qualifying Canadian exploration expenses and flow-through critical mineral mining expenditures and to validly renounce such expenditures to subscribers within the time frames contemplated by the Income Tax Act (Canada); the absence of material changes to current tax legislation or its interpretation; the Company’s ability to carry out its planned exploration programs at the Fishpot Project and the Millar Project.

Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this news release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Except as required by law, GoldInxs undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — GoldInxs Mining Corp. (the “Company” or “GoldInxs”) is pleased to announce a private placement of units (the “Units”) and Critical Mineral Exploration Tax Credit (“CMETC”) flow-through units (the “FT Units”) of the Company at a price of $0.11 per Unit and $0.13 per FT Unit for aggregate gross proceeds of up to approximately $1,150,000 (the “Offering”). Each Unit will consist of one common share of the Company and one common share purchase warrant (a “Warrant”). Each FT Unit will consist of one common share of the Company which will qualify as a “flow-through share” within the meaning of the Income Tax Act (Canada), and one Warrant.

Each whole Warrant will entitle the holder thereof to purchase one common share of the Company at a price of $0.25 at any time on or before the date which is 24 months after the closing date of the Offering, subject to the Acceleration Provision (as defined herein).  If the closing price of the Company’s common shares on the TSX Venture Exchange (the “TSXV”) (or such other principal exchange on which the common shares may be traded at such time) is equal to or greater than $0.50 for a period of ten consecutive trading days, the Company may, at its sole option, accelerate the expiry date of the Warrants to the date which is thirty days following the date upon which notice of the accelerated expiry date is provided by the Company (given by way of news release) (the foregoing the “Acceleration Provision”).

The Company plans to use the net proceeds of the Offering towards the exploration work and other operations at the Company’s flagship Fishpot Project in Central British Columbia among other flow-through eligible expenses, such as exploration, drilling, and sampling programs, and for general working capital purposes.

The Offering is scheduled to close on or about September 30, 2026 and is subject to receipt of all applicable regulatory approvals, including the approval of the TSXV. The securities issued in connection with the Offering are subject to a four-month hold period, in accordance with applicable securities laws and TSXV policies. 

In connection with the Offering, the Company may pay finders’ fees of up to 7% of the gross proceeds raised by the Company for the sale of Units and FT Units to subscribers directly introduced to the Company by eligible finders. In addition, the Company may issue to eligible finders non-transferable finder warrants of up to 7.0% of the aggregate number of the Units and FT Units sold to subscribers directly introduced to the Company by such eligible finders. Each finders’ warrant will entitle the holder to acquire one common share of the Company at a price of $0.11 per common share in respect of Units, or $0.13 per common share in respect of FT Units, for a term of 24 months from the date of closing of the Offering.

The purchase of securities under the Offering by related parties are expected to constitute “related party transactions” of the Company under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). It is expected pursuant to sections 5.5(b) and 5.7(1)(a) of MI 61-101, the Company will be exempt from obtaining formal valuation and minority approval of the Company’s shareholders respecting the purchase of securities under the Offering by related parties as the fair market value of securities to be purchased under the Offering is expected to be below 25% of the Company’s market capitalization as determined in accordance with MI 61-101.

Marketing Engagement

The Company announces that it has engaged Outside The Box Capital Inc. (“OTB”) of Oakville, Ontario as part of its awareness efforts to provide digital communications services under a marketing services agreement dated September 21, 2026 (the “OTB Agreement”), with services and promotional activity to commence on or after September 28, 2026. Under the OTB Agreement, OTB will distribute Company content, including video, and conduct investor communications on social media. The Agreement has a term of three (3) months, from September 28, 2026, to December 28, 2026.  For its services, the Company has agreed to pay OTB a total cash fee of $50,000, plus applicable taxes. The Company and OTB act at arm’s length, and no securities-based compensation, including options, forms part of this engagement. OTB can be contacted at 2202 Green Orchard Place, Oakville, Ontario L6H 4V4, by email at jason@outsidethebox.capital, or by telephone at (289) 259-4455. The OTB Service Agreement is subject to acceptance by the TSX Venture Exchange.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. The securities offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements.  

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Authorised for release by the Board of GoldInxs Mining Corp.

About GoldInxs

GoldInxs Mining Corp. (TSXV:INXS, OTCQB: INXGF) is a Canadian mineral exploration company focused on discovering and advancing a high-quality gold and copper project in Central British Columbia. The Company’s flagship asset is the Fishpot Property, a large epithermal gold system in central British Columbia with Blackwater-style exploration potential, and in the same region as Artemis Gold’s Blackwater Mine and Evolution Mining’s optioned Clisbako property. The Company is listed on the TSX Venture Exchange under the symbol INXS and on the OTCQB Venture Market under the symbol INXGF, and is led by an experienced management and technical team committed to disciplined exploration and value creation for shareholders.

Website: www.goldinxs.com     |     LinkedIn: LINK     |     Twitter/X: LINK

Further Information:

Barry Miller  
Executive Chairman and Director
GoldInxs Mining Corp.
T: 778.232.1878
E: barry@goldinxs.com

Forward Looking Statements:

This news release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, “expects”, “is expected”, “anticipates”, “intends”, “believes”, or variations of such words and phrases or state that certain actions, events or results “may” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include, but are not limited to, statements relating to: the completion and closing of the Offering on the expected terms; the anticipated closing date of the Offering; the approval of the TSXV and receipt of all applicable regulatory approvals; the use of net proceeds from the Offering; the qualification of the FT Unit securities as “flow-through shares” within the meaning of the Income Tax Act (Canada) and the Company’s ability to incur and renounce qualifying Canadian exploration expenses and flow-through critical mineral mining expenditures to subscribers; the Company’s planned exploration work, drilling and sampling programs at the Fishpot Project and the Millar Project; the payment of finders’ fees and the issuance of finder warrants in connection with the Offering; the expected participation in the Offering by related parties and the availability of exemptions from the formal valuation and minority approval requirements of Multilateral Instrument 61-101.

Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including, but not limited to: the Company’s ability to complete the Offering on the terms described herein; the receipt of all necessary regulatory approvals, including the conditional approval of the TSXV; general market and economic conditions; the Company’s ability to incur qualifying Canadian exploration expenses and flow-through critical mineral mining expenditures and to validly renounce such expenditures to subscribers within the time frames contemplated by the Income Tax Act (Canada); the absence of material changes to current tax legislation or its interpretation; the Company’s ability to carry out its planned exploration programs at the Fishpot Project and the Millar Project.

Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this news release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Except as required by law, GoldInxs undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreement

NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (“TIRC”), has entered into a binding term sheet with Psyence Labs Ltd. (“PsyLabs”) under which PsyLabs will grant TIRC an exclusive license, supply and wholesale distribution arrangement for PsyLabs’ pharmaceutical-grade ibogaine in the United States. The term sheet is binding on the parties and is to be superseded by a definitive agreement, which the parties have agreed to conclude on or before November 30, 2026; if a definitive agreement is not signed by that date, the term sheet will lapse.

Under the term sheet, PsyLabs will grant TIRC an exclusive license in the United States to PsyLabs’ know-how, trade secrets, cultivation, extraction and processing methods, analytical methods, specifications, standard operating procedures, batch records and technical and regulatory information relating to its pharmaceutical-grade ibogaine hydrochloride, to the extent necessary or useful to develop, manufacture and commercialize ibogaine drug candidates in the United States. PsyLabs will be TIRC’s exclusive supplier of ibogaine, and TIRC will be appointed PsyLabs’ exclusive wholesaler and distributor of that product in the United States. PsyLabs retains all rights outside the United States. In consideration, TIRC will pay PsyLabs development and regulatory milestone payments totaling up to approximately US$1.3 million for the first drug candidate, an annual exclusivity fee commencing on the first anniversary of the first FDA approval and creditable against royalties, and a low single-digit percentage royalty on net sales of each drug candidate, together with a margin-sharing arrangement on any resale of product by TIRC. TIRC’s exclusivity is conditional on TIRC sourcing all of its ibogaine requirements for the United States from PsyLabs, subject to customary supply-failure step-in rights, and is expected to be subject to minimum development or sales performance thresholds to be set out in the definitive agreement. PsyLabs, which is a significant shareholder of Psyence BioMed and in which Psyence BioMed holds an ownership interest, is licensed in its operating jurisdiction to cultivate, extract and export ibogaine and operates from an ISO 22000 and GMP-compliant production and processing facility.

TIRC, which is wholly-owned and financed by Psyence BioMed, intends to pursue a U.S. ibogaine development program under the license, subject to conclusion of the definitive agreement and to the manufacturing, nonclinical and regulatory work required before any clinical investigation can be proposed.

“Exclusivity matters. This term sheet is intended to give TIRC a defined position in U.S. ibogaine development, backed by access to PsyLabs’ material, manufacturing know-how and technical documentation. For any federal agency, state programme or clinical partner, we believe that the question of who to work with on ibogaine in the USA has a clear answer.”

— Jody Aufrichtig, Chief Executive Officer, Psyence BioMed and Texas Ibogaine Research Corporation

“This term sheet is intended to give TIRC access to PsyLabs’ material, know-how and technical and regulatory documentation, which we believe will allow our development programme to start at speed rather than from scratch. We believe that very few compounds anywhere come with this much of the groundwork already done; and most importantly we believe that it gets us closer to being able to offer treatment to patients in need.”

— Dr. John Thorne, Project Lead, Texas Ibogaine Research Corporation

The Company intends to provide further updates as TIRC advances through manufacturing, regulatory and clinical milestones under the license, including conclusion of the definitive agreement.

ABOUT PSYENCE BIOMED
Psyence Biomedical Ltd. (Nasdaq: PBM) is a Nasdaq-listed company with its subsidiary, Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine to be listed on Nasdaq. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.

ABOUT PSYLABS
PsyLabs is a neuroplastogen active pharmaceutical ingredient development company, federally licensed in its operating jurisdiction to cultivate, extract and export psilocybin mushrooms and other neuroplastogen compounds, including psilocybin, psilocin, mescaline, ibogaine and dimethyltryptamine, to lawful medical and research markets. PsyLabs operates from an ISO 22000 and GMP-compliant facility, with a focus on natural compound purification, regulatory support and global distribution. www.psylabs.life

CONTACTS
Psyence Biomedical Ltd. • ir@psyencebiomed.com • media@psyencebiomed.com • info@psyencebiomed.com • +1 416-477-1708
Investor contact: Michael Kydd, Investor Relations Advisor — michael@psyencebiomed.com

FORWARD-LOOKING STATEMENTS
This communication contains “forward-looking statements” within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995. These include statements regarding the negotiation and conclusion of a definitive agreement with PsyLabs; the scope, duration, exclusivity and expected benefits of the license, supply and distribution arrangements; the milestone, exclusivity fee and royalty payments that may become payable; TIRC’s intended role in United States ibogaine development, supply and distribution; the manufacturing, nonclinical, regulatory and clinical activities TIRC intends to pursue; and the Company’s expected participation in federal and state programs. Forward-looking statements may be identified by words such as “will,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates” and similar expressions.

These statements are based on assumptions regarding government policy, continued interest in regulated neuroplastogen research, the availability of lawful development pathways, and the Company’s ability to maintain licenses, permits, supply arrangements and third-party relationships. These assumptions may prove incorrect. Risks and uncertainties that could cause actual results to differ materially include the possibility that the definitive agreement is not concluded by November 30, 2026, or at all, or is concluded on terms that differ from the term sheet; that the license is terminated, narrowed, converted to a non-exclusive license or disputed; that TIRC’s exclusivity becomes subject to minimum performance thresholds that TIRC does not meet; that licensed rights prove insufficient for the intended program; dependence on PsyLabs as exclusive licensor and supplier, and TIRC’s obligation to source ibogaine exclusively from PsyLabs; that the arrangements are between related parties and the terms agreed may differ from those that would be agreed between unrelated parties; changes in law, regulation or enforcement priorities in the United States, Southern Africa or elsewhere; the continuing status of ibogaine as a controlled substance; clinical, regulatory and approval risks; competition, including from parties developing ibogaine outside the licensed estate; financing risks; and the Company’s ability to maintain compliance with Nasdaq continued listing standards. This list is not exhaustive. These risks should be considered together with the risk factors described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026 and in the Company’s other filings with the U.S. Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Readers should not place undue reliance on forward-looking statements, which speak only as of the date made. Except as required by law, the Company undertakes no obligation to update such statements.

The Company makes no medical, treatment or health benefit claims regarding its proposed products. The U.S. Food and Drug Administration, Health Canada and other regulatory authorities have not approved ibogaine or the Company’s other neuroplastogen compounds for therapeutic use, and their safety and efficacy have not been established through authorized clinical research. Rigorous scientific research and clinical trials are required. Any references to ibogaine stock, inventory or doses are the Company’s best estimates only. References to GMP-compliant mean production in a facility designed, operated and controlled in accordance with applicable Good Manufacturing Practice standards, and do not themselves constitute a representation of formal certification or approval by any regulatory authority unless expressly stated. References to a planned clinical trial describe an activity under evaluation only; no trial has been commenced, and no regulatory application in respect of it has been filed or accepted.

This communication is not an offer to sell or a solicitation of an offer to buy any securities.